Interleukin sees shake-up at top management

Related News

Closing the Deal: Stop clicking, start selling [May 7, 2012]

Closing the Deal: The 80/20 Rule: Is it reality or is it an incongruity? [April 26, 2012]

Closing the Deal: Selling to pain – the greatest motivator [April 3, 2012]

Closing the Deal: The missing link: uncovering the true value of financial benefits [March 27, 2012]

Closing the Deal: Hearing Voices is good for the Prospect [March 13, 2012]

Two key executives of Interleukin Genetics Inc. have stepped down, and the board chairman has stepped in until a new CEO is brought on.

Interleukin reported that CEO Tim Richerson is resigning to pursue other opportunities. Additionally, the company said that chief strategy officer David Finkelstein has resigned his position, effective immediately. No reason was given.

Richerson will leave Waltham-based Interleukin on July 31, and until that time will oversee operations of the company's Alan James Group business, according to officials.

Thomas Curran, Interleukin's chairman of the board, will serve as interim CEO while the board of directors conducts a search for a new CEO.

Interleukin also reports that James Weaver, currently vice president of Alticor Corporate Enterprises, has been named to the board to serve as a director.

Interleukin reported a net loss for 2006 of $6.9 million on revenue of $4.7 million. The company employs 27 workers.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.